AU2005287743B2 - Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof - Google Patents

Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof Download PDF

Info

Publication number
AU2005287743B2
AU2005287743B2 AU2005287743A AU2005287743A AU2005287743B2 AU 2005287743 B2 AU2005287743 B2 AU 2005287743B2 AU 2005287743 A AU2005287743 A AU 2005287743A AU 2005287743 A AU2005287743 A AU 2005287743A AU 2005287743 B2 AU2005287743 B2 AU 2005287743B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
release
rotigotine
microspheres
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005287743A
Other languages
English (en)
Other versions
AU2005287743A1 (en
Inventor
Luping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Luye Pharmaceutical Co Ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Publication of AU2005287743A1 publication Critical patent/AU2005287743A1/en
Application granted granted Critical
Publication of AU2005287743B2 publication Critical patent/AU2005287743B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005287743A 2004-09-21 2005-09-21 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof Ceased AU2005287743B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410077961.9 2004-09-21
CN200410077961 2004-09-21
PCT/CN2005/001521 WO2006032202A1 (fr) 2004-09-21 2005-09-21 Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation

Publications (2)

Publication Number Publication Date
AU2005287743A1 AU2005287743A1 (en) 2006-03-30
AU2005287743B2 true AU2005287743B2 (en) 2011-09-29

Family

ID=36089849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005287743A Ceased AU2005287743B2 (en) 2004-09-21 2005-09-21 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof

Country Status (9)

Country Link
US (2) US8691277B2 (enExample)
EP (1) EP1797871B1 (enExample)
JP (1) JP5081622B2 (enExample)
KR (1) KR20070059161A (enExample)
AU (1) AU2005287743B2 (enExample)
CA (1) CA2581143C (enExample)
ES (1) ES2536460T3 (enExample)
PL (1) PL1797871T3 (enExample)
WO (1) WO2006032202A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US8475829B2 (en) * 2006-04-06 2013-07-02 Nupathe Inc. Implants for the treatment of dopamine associated states
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
CA2654719A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising slv308 and a l-dopa
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
US20090304794A1 (en) * 2008-06-09 2009-12-10 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
EP2452677A1 (en) 2008-09-29 2012-05-16 Wockhardt Limited Extended release dosage form of ropinirole
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
AU2010266285A1 (en) * 2009-07-02 2012-02-09 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011012721A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Carrier linked pramipexole prodrugs
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
AU2011334494B2 (en) * 2010-11-25 2015-11-05 Geneora Pharma (Shijiazhuang) Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
EA201300607A8 (ru) * 2010-12-02 2014-02-28 Ратиофарм Гмбх Ионная жидкость ротиготина
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
WO2019234069A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
WO2002015903A2 (de) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Neue pharmazeutische zusammensetzung zur verabreichung von n-0923

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
DE69734060T2 (de) * 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
EP0930874A2 (en) 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
JP3663271B2 (ja) * 1997-01-24 2005-06-22 シュバルツ ファルマ アクチェンゲゼルシャフト 新規の分枝鎖エステル及びその製法
ATE428371T1 (de) * 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
MEP19408A (en) * 1998-12-16 2010-06-10 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
GB9828861D0 (en) * 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
JP4540280B2 (ja) 1999-07-09 2010-09-08 ベーテーエス ホールディング インターナショナル ベー ヴィ 光学走査装置
JP4287613B2 (ja) 2000-04-28 2009-07-01 田辺三菱製薬株式会社 マイクロスフェアの製法
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
KR20040005936A (ko) * 2001-04-26 2004-01-16 컨트롤 딜리버리 시스템즈 인코포레이티드 공동약물을 함유하는 서방 약물 전달 시스템
EP1572154B1 (en) * 2002-11-18 2012-02-01 Rutgers, The State University of New Jersey Medical devices employing novel polymers
EP1610791B1 (en) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
WO2002015903A2 (de) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Neue pharmazeutische zusammensetzung zur verabreichung von n-0923

Also Published As

Publication number Publication date
EP1797871A4 (en) 2012-11-28
WO2006032202A1 (fr) 2006-03-30
CA2581143C (en) 2015-03-31
US20080260846A1 (en) 2008-10-23
US8691277B2 (en) 2014-04-08
ES2536460T3 (es) 2015-05-25
US9220782B2 (en) 2015-12-29
JP2008513524A (ja) 2008-05-01
CA2581143A1 (en) 2006-03-30
JP5081622B2 (ja) 2012-11-28
EP1797871A1 (en) 2007-06-20
KR20070059161A (ko) 2007-06-11
HK1107012A1 (en) 2008-03-28
EP1797871B1 (en) 2015-02-25
PL1797871T3 (pl) 2015-07-31
AU2005287743A1 (en) 2006-03-30
US20140255488A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
US9220782B2 (en) Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
JP6067803B2 (ja) ロチゴチン、その誘導体、又はロチゴチン若しくはその誘導体の薬学的に許容可能な塩の組成物
EP2982367B1 (en) Pharmaceutical composition for parenteral administration, containing donepezil
BR112013027235B1 (pt) Composição farmacêutica, seu uso, e formulação de microsferas para injeção de liberação sustentada
EP2910242B1 (en) Durable analgetic sebacoyl dinalbuphine ester-plga controlled release formulation
WO2003004024A1 (en) Injectable sustained-release microspheres of huperzine a compounds
CN106924172B (zh) 一种石杉碱甲溶致液晶制剂及其制备方法
KR101663560B1 (ko) 균일한 서방출성 미립구의 제조방법
CN1762495B (zh) 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
CN102784111A (zh) 一种多巴胺受体激动剂类药物的缓释制剂
US20180177777A1 (en) Formulations for mitigating opioid overdose and methods of making and using the same
CN103494820B (zh) 一种尼莫地平/川芎嗪双载药plga纳米粒及其制备方法
HK1107012B (en) Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
EP4491173A1 (en) Method for preparing microsphere with improved suspension performance, using coacervation
TW202038910A (zh) 納曲酮注射型緩釋製劑
CN116850146A (zh) 伏硫西汀自由碱或其药用盐长效缓释制剂及其制备方法
WO2023131608A1 (en) Controlled release compositions
WO2006066509A1 (fr) Préparation microsphérique à libération prolongée injectable de dérivés de 3,3-diphénylpropylamine servant d'antagonistes du récepteur muscarinique
TW202339751A (zh) 包含有卡利拉嗪自由鹼粒子的可注射貯釋配方
HK1186978B (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
TR2022013222A1 (tr) Naltrekson i̇çeren i̇n si̇tu jel oluşturan çözelti̇ler

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired